Biomerica's Medicare Reimbursement Boosts inFoods® IBS Orders, Engages B. Riley for Strategic Options
Event summary
- Medicare-related test orders for inFoods® IBS surged 120% in September 2026 compared to August, with 100% of initial valid claims paid at the full CMS rate of $300.
- Biomerica engaged B. Riley Securities to evaluate strategic opportunities, including partnerships and business combinations.
- Total operating expenses decreased approximately 14% year over year, while over-the-counter sales increased approximately 81%.
- Cash and cash equivalents more than doubled to approximately $2.7 million at August 31, 2026, from $1.3 million at May 31, 2026.
The big picture
Biomerica's focus on expanding Medicare reimbursement for inFoods® IBS and engaging B. Riley Securities for strategic options reflects a broader trend in the biomedical technology sector towards leveraging regulatory pathways and strategic partnerships to drive growth. The company's cost reduction efforts and increased cash position provide a solid foundation for pursuing these opportunities, but the success of these initiatives will depend on sustained physician adoption and the execution of strategic deals.
What we're watching
- Medicare Adoption
- How the sustained increase in Medicare-related test orders will impact inFoods® IBS commercialization and physician adoption.
- Strategic Options
- Whether Biomerica's engagement with B. Riley Securities will lead to meaningful partnerships or business combinations.
- Financial Discipline
- The pace at which Biomerica can maintain cost discipline while expanding its revenue base through contract development and manufacturing opportunities.
Related topics